Abstract: The present disclosure is directed to isolated or recombinant antigen binding proteins, such as antibodies, which bind to coronavirus spike (S) protein receptor binding domain (RBD), including S protein RBD from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The present disclosure is also directed to the use of the isolated or recombinant proteins as therapeutic, prophylactic and/or diagnostic agents for respiratory conditions associated with coronavirus infection, such as infection by SARS-CoV-2. The present disclosure is also related to nucleic acid sequences which encode said antigen binding proteins and their expression in recombinant host cells.